Sun Pharma

Sun Pharma et Philogen concluent un accord exclusif de distribution, de licence et d’approvisionnement pour la commercialisation de la spécialité NIDLEGY™ en Europe, en Australie et en Nouvelle-Zélande USA – Français USA – English USA – English APAC – English USA – español USA – Deutsch

by

MUMBAI, Inde et SIENNE, Italie, 31 mai 2023 /PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters : SUN.BO), (Bloomberg : SUNP IN), (NSE : SUNPHARMA), (BSE : 524715) avec ses filiales et/ou sociétés associées, « Sun Pharma ») et Philogen S.p.A (BIT : PHIL) ont annoncé aujourd’hui qu’ils ont conclu un accord de licence pour la commercialisation du produit de spécialité de Philogen, le Nidlegy™ … Read more

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA – English USA – English

by

MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ (Daromun) in … Read more

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand USA – English USA – English

by

MUMBAI, India and SIENA, Italy, May 30, 2023 /PRNewswire/ — Sun Pharmaceutical Industries Limited (Reuters: SUN.BO), (Bloomberg: SUNP IN), (NSE: SUNPHARMA), (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ (Daromun) in … Read more